Ovid Therapeutics is a clinical-stage biopharmaceutical company developing medicines for patients and families living with rare neurological disorders.
We work with Ovid on an integrated corporate communications strategy spanning public relations, social media and digital communications. As a relatively young company, Ovid’s communication objectives centered around raising their profile and building relationships with key audiences, including media, investors and patient communities.
With a refreshed brand in 2016, we launched Ovid’s new website and communications strategy to reflect its status as a maturing company and evolved messaging.
The new corporate narrative and media coverage focused on Ovid’s innovative approach to business, from clinical trial design to groundbreaking deal structures.
To deepen Ovid’s connection with their patient communities, we launched an organic and paid social campaign strategy to support Ovid’s direct interaction with the family members and caretakers of Angelman and Fragile X syndrome patients in order to educate and learn from members of the community while also highlighting Ovid’s progress and commitment to these disease areas.